Evidence map›Paper›PMID 38750069›Full record

ArticleScientific reports2024

Mechanistic insights into SARS-CoV-2 spike protein induction of the chemokine CXCL10.

Davoud Ghazanfari, Maria Cecilia Courreges, Lydia E Belinski, Michael J Hogrell, Jacob Lloyd, Stephen C Bergmeier, Kelly D McCall, Douglas J Goetz

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. iPSC-derived human cortical organoids display profound alterations of cellular homeostasis following SARS-CoV-2 infection and Spike protein exposure.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  3. Article
  4. Article
  5. Structural proteins of human coronaviruses: what makes them different?Frontiers in cellular and infection microbiology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Davoud GhazanfariDepartment of Chemical and Biomolecular Engineering, Ohio University, Athens, OH, 45701, USA.
Maria Cecilia CourregesDepartment of Specialty Medicine, Ohio University, Athens, OH, 45701, USA.
Lydia E BelinskiDepartment of Chemical and Biomolecular Engineering, Ohio University, Athens, OH, 45701, USA.
Michael J HogrellDepartment of Chemical and Biomolecular Engineering, Ohio University, Athens, OH, 45701, USA.
Jacob LloydDepartment of Chemical and Biomolecular Engineering, Ohio University, Athens, OH, 45701, USA.
Stephen C BergmeierBiomedical Engineering Program, Ohio University, Athens, OH, 45701, USA.
Kelly D McCallDepartment of Specialty Medicine, Ohio University, Athens, OH, 45701, USA.
Douglas J GoetzDepartment of Chemical and Biomolecular Engineering, Ohio University, Athens, OH, 45701, USA. goetzd@ohio.edu.

Funding

Novel Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as Therapeutic AgentsR15GM110602 · NIGMS · OHIO UNIVERSITY ATHENS · PI GOETZ, DOUGLAS J · 2016 to 2025
$1.5M
Emergent Ventures at the Mercatus Center, George Mason University Fast GrantNational Science Foundation, United States CDS&E 195331NIGMS NIH HHS R15 GM110602NIH HHS R15GM110602
6 · The paper itself

Abstract

During a SARS-CoV-2 infection, macrophages recognize viral components resulting in cytokine production. While this response fuels virus elimination, overexpression of cytokines can lead to severe COVID-19. Previous studies suggest that the spike protein (S) of SARS-CoV-2 can elicit cytokine production via the transcription factor NF-κB and the toll-like receptors (TLRs). In this study, we found that: (i) S and the S2 subunit induce CXCL10, a chemokine implicated in severe COVID-19, gene expression by human macrophage cells (THP-1); (ii) a glycogen synthase kinase-3 inhibitor attenuates this induction; (iii) S and S2 do not activate NF-κB but do activate the transcription factor IRF; (iv) S and S2 do not require TLR2 to elicit CXCL10 production or activate IRF; and (v) S and S2 elicit CXCL10 production by peripheral blood mononuclear cells (PBMCs). We also discovered that the cellular response, or lack thereof, to S and S2 is a function of the recombinant S and S2 used. While such a finding raises the possibility of confounding LPS contamination, we offer evidence that potential contaminating LPS does not underly induced increases in CXCL10. Combined, these results provide insights into the complex immune response to SARS-CoV-2 and suggest possible therapeutic targets for severe COVID-19.

Indexed as

Chemokine CXCL10COVID-19SARS-CoV-2Spike Glycoprotein, CoronavirusHumansLeukocytes, MononuclearMacrophagesNF-kappa BTHP-1 CellsChemokine CXCL10NF-kappa BSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2CXCL10 (IP-10)Glycogen Synthase Kinase-3IRFNF-κBSARS-CoV-2-Spike ProteinTLR2

Identifiers

PMID38750069
PMCPMC11096305

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.